Kyntra Bio Inc（KYNB）資訊與事件KYNBKyntra Bio Inc

Kyntra Bio Signs Agreement Amendment with NQ Project Phoebus, Reducing Payment Obligations to $65M

Kyntra Bio announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, materially reducing its payment obligations under the agreement in exchange for an accelerated upfront payment. The amendment reduces the maximum aggregate payments under the agreement from $125M to $65M. Kyntra Bio made a $42.6M accelerated upfront payment to NQ Project Phoebus, bringing total payments made to date to $50M, a full return of NQ Project Phoebus's invested capital. Remaining payments, capped at $15M, will be paid from 50% of the revenue Kyntra Bio receives from Astellas in the Astellas territories excluding Japan. Once the $15M cap is reached, the amended agreement will terminate. Kyntra Bio will retain all subsequent Evrenzo royalties in the Astellas territories.

Kyntra Bio CEO Emphasizes Advancing Clinical Trials

"We continue to make progress across our oncology and rare disease portfolio and remain laser-focused on advancing toward our goal of initiating a pivotal Phase 3 trial of roxadustat in LR-MDS in the fourth quarter of this year and conducting an interim analysis of the Phase 2 trial of FG-3246 in mCRPC, also in the fourth quarter of this year," said Thane Wettig, Chief Executive Officer of Kyntra Bio. "We believe we have the substrate that will enable us to create significant value for patients and stakeholders as we advance our pipeline and look forward to providing additional updates in the coming months."

Kyntra Bio Presents Roxadustat Study Data at EHA 2026

Kyntra Bio announced additional data from the Phase 3 MATTERHORN trial showing improvements in transfusion independence in patients with anemia associated with lower-risk myelodysplastic syndromes treated with roxadustat will be presented as a poster at the European Hematology Association, or EHA, Congress 2026, taking place June 11-14 in Stockholm, Sweden. As previously disclosed, the initial analysis with all of the patients who participated in the Phase 3 MATTERHORN trial showed that more patients receiving roxadustat achieved transfusion independence vs. placebo. The presentation highlights data from a post hoc analysis of the entire trial population, demonstrating that roxadustat led to similar rates of transfusion independence in both RS+ and RS- patients. In RS- patients, which comprised 84 of the 140 patients enrolled in the trial, treatment with roxadustat led to transfusion independence for greater than or equal to 8 weeks over 28 weeks in 48% of patients vs. 28% for placebo. The presentation at EHA also provides additional details on the subgroup of patients who met the criteria of HTB per IWG-2018, where roxadustat achieved clinically meaningful efficacy in patients with LR-MDS and HTB with higher rates of greater than or equal to 8-, 12-, 16-week RBC TI vs placebo. TEAEs were generally lower grade and managed medically with no new safety signals. The poster presentation is scheduled for the poster session taking place on June 12. The pivotal Phase 3 trial protocol of roxadustat for the treatment of anemia in patients with LR-MDS and high transfusion burden is being finalized based on feedback received from the FDA.